enrofloxacin has been researched along with Intestinal Diseases in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bughio, S; Dai, X; Guo, M; Ren, W; Sun, Y; Wang, L; Zhang, Y | 1 |
| Bell, D; Cornell, KK; Epstein, J; Schmiedt, CW; Stratton-Phelps, M; Torres, BT; Uhl, EW; Zimmerman, S | 1 |
2 other study(ies) available for enrofloxacin and Intestinal Diseases
| Article | Year |
|---|---|
E. coli infection modulates the pharmacokinetics of oral enrofloxacin by targeting P-glycoprotein in small intestine and CYP450 3A in liver and kidney of broilers.
Topics: Animals; Antineoplastic Agents; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporter, Subfamily B, Member 1; Avian Proteins; Chickens; Cytochrome P450 Family 3; Enrofloxacin; Escherichia coli Infections; Female; Fluoroquinolones; Intestinal Diseases; Intestinal Mucosa; Intestines; Kidney; Liver; Male; Poultry Diseases; Verapamil | 2014 |
Treatment of intestinal pythiosis in a dog with a combination of marginal excision, chemotherapy, and immunotherapy.
Topics: Animals; Anti-Infective Agents; Dog Diseases; Dogs; Enrofloxacin; Fluoroquinolones; Intestinal Diseases; Itraconazole; Male; Naphthalenes; Pythiosis; Pythium; Terbinafine; Vaccines | 2012 |